〜1999

    1999

  1. Hazeki, K., O. Hazeki, T. Matsuo, T. Seya, T. Yamashita, S. Nagasawa, H. Band, and M. Ui. 1999. Role of Syk in Fcγ receptor-coupled tyrosine phosphorylation of Cbl in a manner susceptible to inhibition by protein kinase C. Eur. J. Immunol. 29: 3302-3312.
  2. Shida, K., M. Nomura, M. Kurita-Taniguchi, M. Matsumoto, K. Toyoshima, and T. Seya. 1999. The 3'-UT of the ubiquitous message of human CD46 confers selective suppression of protein production in murine cells. Eur. J. Immunol. 29: 3603-3608.
  3. Nomura, M., K. Shida, A. Tsujimura, M. Matsumoto, Y. Matsuda, K. Toyoshima, and T. Seya. 1999. Membrane and secretory forms of mouse membrane cofactor protein (CD46) generated from a single gene through alternative splicing. Immunogenetics 50: 245-254.
  4. Kawano, M., T. Seya, I. Koni, and H. Mabuchi. 1999. Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 116: 542-546.
  5. Kurita, M., M. Matsumoto, S. Tsuji, M. Kawakami, Y. Suzuki, H. Hayashi, K. Toyoshima, and T. Seya. 1999. Antibody-independent classical complement pathway activation and homologous C3 deposition in xeroderma pigmentosum cell lines. Clin. Exp. Immunol. 116: 547-553.
  6. Begum, N. A., S. Tsuji, M. Nomura, M. Matsumoto, I. Azuma, A. Hayashi, T. Seya, and K. Toyoshima. 1999. A BCG-CWS-regulated gene in human monocytes by differential display: Identification of a human homologue of chicken MD-1. Biochem. Biophys. Res. Commun. 256: 325-329.
  7. Murakami, Y., A. Fukui, T. Seya, S. Ueda, and S. Nagasawa. 1999. Effect of mutations at the residues R25, D27, P69, and N70 of B95a-MCP on receptor activities for the measles viruses Nagahata wild-type strain and CAM vaccine strain. Int. J. Mol. Med. 3: 25-32.

    1998

  8. Tsujimura, A., K. Shida, K. Kitamura, M. Nomura, J. Takeda, H. Tanaka, M. Matsumoto, K. Matsumiya, A. Okuyama, Y. Nishimune, M. Okabe, and T. Seya. 1998. Molecular cloning of murine homologue of membrane cofactor protein (MCP, CD46): preferential expression in testicular germ cells. Biochem. J. 330: 163-168.
  9. Doi, Y., M. Kurita, M. Matsumoto, T. Kondo, T. Noda, Sa. Tsukita, Sh. Tsukita, and T. Seya. 1998. Moesin is not a receptor for measles virus entry into mouse embryonic stem cells. J. Virol. 72: 1586-1592.
  10. Seya, T., N. A. Begum, and M. Masumoto. 1998. Mycoplasma origin of tumor cell protein. Nature Med. 4: 133.
  11. Murakami, Y., T. Seya, M. Kurita, A. Fukui, S. Ueda, and S. Nagasawa. 1998. Molecular cloning of membrane cofactor protein (MCP, CD46) on B95a cell, an Epstein-Barr virus-transformed marmoset B cell line: B95a MCP is susceptible to infection by the CAM but not the Nagahata strain of the measles virus. Biochem. J. 330: 1351-1359.
  12. Mikata, S., S. Miyagawa, K. Iwata, S. Nagasawa, M. Hatanaka, M. Matsumoto, W. Kamiike, H. Matsuda, R. Shirakura, and T. Seya. 1998. Regulation of human complement-mediated swine endothelial cell lysis by surface-bound form of human C4b-binding protein. Transplantation 65: 363-368.
  13. Hatanaka, M., T. Seya, S. Miyagawa, M. Matsumoto, T. Hara, K. Tanaka, H. Hayashi, and A. Shimizu. 1998. Homodimerization of a GPI-anchored complement regulatory protein CD59 on the surface of Hela and CD59-transfected CHO cells. J. Biochem. (Tokyo) 123: 579-586.
  14. Hara, T., Y. Suzuki, T. Nakazawa, H. Nishimura, S. Nagasawa, M. Nishiguchi, M. Matsumoto, M. Hatanaka, M. Kitamura, and T. Seya. 1998. Post-translational modification and intracellular localization of a splice product of CD46 cloned from the human testis: Role of the intracellular domains in O-glycosylation. Immunology 93: 546-555.
  15. Matsumoto, M., M. Nishiguchi, S. Kikkawa, H. Nishimura, S. Nagasawa, and T. Seya. 1998. Structural and functional properties of complement-activating protein M161Ag, a Mycoplasma fermentans gene product that induces cytokine production by human monocytes. J. Biol. Chem. 273: 12407-12414.
  16. Sakata, H., M. Kurita, Y. Murakami, S. Nagasawa, N. Watanabe, S. Ueda, M. Matsumoto, T. Sato, F. Kobune, and T. Seya. 1998. A Japanese wild-type measles virus strain inducing predominant early down-regulation of CD46 . Biol. Pharmac. Bull. 21: 1121-1127.
  17. Mikata, S., S. Miyagawa, K. Suzuki, S. Nezu, W. Kamiike, R. Shirakura, H. Matsuda, M. Hatanaka, M. Matsumoto, T. Seya, and S. Nagasawa. 1998. A monomeric human C4b-binding protein (C4bp) more efficiently inactivates C3b than natural C4bp: Participation of C-terminal domains in factor I-cofactor activity. Molec. Immunol. 35: 537-544.
  18. Saeki, Y., T. Seya, O. Hazeki, K. Hazeki, M. Ui, and H. Akedo. 1998. Phosphatidylinositol 3 kinase inhibitors block matrix adhesion and experimental metastasis of high metastatic mouse hepatoma clones. J. Biochem. (Tokyo) 124: 1020-1025.
  19. 124. Hatanaka, M., T. Maeda, T. Ikemoto, H. Mori, T. Seya, and A. Shimizu. 1998. Expression of caveolin-1 in human T cell leukemia cell lines. Biochem. Biophys. Res. Commun. 253: 382-387.

    1997

  20. Seya,T., M. Kurita, K. Iwata, Y. Yanagi, K. Tanaka, M. Hatanaka, M. Matsumoto, A. Hirano, S. Ueda, and S. Nagasawa. 1997. The CD46 transmembrane domain is required for efficient measles virus-mediated syncytium formation. Biochem. J. 322: 135-144.
  21. Kitamura, M., K. Matsumiya, M. Yamanaka, S. Takahara, T. Hara, M. Matsumoto, M. Namiki, A. Okuyama, and T. Seya. 1997. Possible association of infertility with sperm-specific abnormality of CD46. J. Reprod. Immunol. 33: 83-88.
  22. Hashimoto, C., H. Masuda, M. Ayaki, Y. Suzuki, A. Uenaka, T. Seya, J. Miyoshi, K. Takahashi, and Y. Inui. 1997. Molecular cloning of mouse PGIF, the purified growth inhibitory factor from adult hamster liver, which is a homolog of human arginase. Biochim. Biophys. Acta 1355: 205-208.
  23. Matsumoto, M., J. Takeda, N. Inoue, T. Hara, M. Hatanaka, K. Takahashi, S. Nagasawa, H. Akedo, and T. Seya. 1997. A novel protein which participates in nonself discrimination of malignant cells by homologous complement. Nature Med. 3: 1266-1270.
  24. Miyagawa, S., S. Mikata, H. Tanaka, M. Ikawa, K. Kominami, T. Seya, Y. Nishimune, R. Shirakura, and M. Okabe. 1997. The regulation of membrane cofactor protein (CD46) expression by the 3' untranslated region in transgenic mice. Biochem. Biophys. Res. Commun. 233: 829-833.
  25. Nakagawa, K., H. Sakiyama, T. Fukazawa, M. Matsumoto, M. Takigawa, T. Toyoguchi, and H. Moriya. 1997. Coordinated change between complement C1s production and chondrocyte differentiation in vitro. Cell Tissue Res. 289: 299-305.

    1996

  26. Seya, T., M. Matsumoto, M. Hatanaka, M. Okada, T. Masaki, and K. Iida. 1996. A rapid and efficient purification procedure of human complement receptor type 1 (CR1, CD35). J. Biochem. Biophys. Methods 32: 69-76.
  27. Hatanaka, M., T. Seya, T. Hara, M. Matsumoto, M. Nonaka, J. Takeda, and A. Shimizu. 1996. Mechanisms involved in loss of glycan phosphatidyl inositol-anchored complement regulatory proteins, decay-accelerating factor (DAF, CD55) and CD59, in human leukemia cell lines. Biochem. J. 314: 969-976.
  28. Azuma, A., T. Tsuchiya, and T. Seya. 1996. Complement-dependent tumot cell cytotoxicity. Scand. J. Immunol. 43: 351-353.
  29. Miyagawa, S., S. Mikata, R. Shirakura, H. Matsuda, S. Nagasawa, A. Terado, M. Hatanaka, M. Matsumoto, and T. Seya. 1996. C5b-8 step lysis of swine endothelial cell by human complement and functional feature of transfected CD59. Scand. J. Immunol. 43: 361-366.
  30. Kurita, M., T. Seya, M. Matsumoto, T. Hara, M. Watanabe, and S. Ueda. 1996. Suppression of the cytopathic effect induced by measles virus vaccine strains using monoclonal antibodies against CD46. Vaccine Res. 5: 53-55.
  31. Hirano, A., S. Yant, K. Iwata, J. Korte-Sarfarty, M. Okabe, T. Seya, S. Nagasawa, and T. C. Wong. 1996. Cellular receptor CD46 is down-regulated through recognition of its transmembrane-cytoplasmic domains rather than hemagglutinin-binding domain in cells persistently infected by measles virus. J. Virol. 70: 6929-6936.
  32. Kitamura, M., K. Matsumiya, T. Hara, M. Namiki, T. Seya, and A. Okuyama. 1996. The fertilizing ability of human epididymal sperm. J. Assist. Reprod. Gen. 13: 652-656.
  33. Fukumori, Y., T. Seya, S. Ohnoki, H. Shibata, and H. Yamaguchi. 1996. Levels of complement regulatory proteins, CD35 (CR1), CD55 (DAF) and CD59 on the in vitro storage of X-ray irradiated red blood cells. Vox Sang. 71: 243-244.
  34. Mclaughlin, P. J., S. J. Holland, C. T. Taylor, K. S. Oiah, D. I. Lewis-Jones, T. Hara, T. Seya, and P. M. Johnson. 1996. Soluble CD46 (membrane cofactor protein, MCP) in human reproductive tract fluids. J. Reprod. Immunol. 31: 209-219.
  35. Murakami, Y., T. Seya, M. Kurita, and S. Nagasawa. 1996. Molecular cloning and functional characterization of membrane cofactor protein)/measles virus receptor (MCP, CD46 on Vero cells. Biol. Pharmac. Bull. 19: 1541-1545.
  36. Hara, T., M. Matsumoto, S. Tsuji, S. Nagasawa, A. Hiraoka, T. Masaoka, K. Kodama, T. Horai, T. Sakuma, and T. Seya,. 1996. Enhanced opsonization of drug-induced apoptotic cells of a human lung adenocarcinoma cell line by homologous complement activation. Immunobiol. 196: 491-503.

    1995

  37. Kim. Y. U., T. Kinoshita, H. Molina, D. Hourcade, T. Seya, L. M. Wagner, and V. M. Holers. 1995. Mouse complement regulatory protein CRRY/P65 utilizes the specific mechanisms of both human decay-accelerating factor (DAF) and membrane cofactor protein (MCP). J. Exp. Med. 181: 151-159.
  38. Matsumoto, M., F. Yamashita, K. Iida, M. Tomita, and T. Seya. 1995. Purification and characterization of a human membrane protein that activates the alternative complement pathway and allows the deposition of homologous C3. J. Exp. Med. 181: 115-125.
  39. Iwata, K., T. Seya, Y. Yanagi, J. M. Pesando, P. M. Johnson, M. Okabe, S. Ueda, H. Ariga, and S. Nagasawa. 1995. Diversity of the sites for measles virus infection and for inactivation of complement C3b and C4b on membrane cofactor protein (MCP, CD46). J. Biol. Chem. 270: 15148-15152.
  40. Masaki, T., M. Matsumoto, I. Nakanishi, T. Hara, H. Kitamura, and T. Seya. 1995. Covalently-bound human C4b dimers consisting of C4B isotype show higher hemolytic activity than those of C4A in the C3-bypass complement pathway. Molec. Immunol. 32: 21-26.
  41. Moutabarrik, A., I. Nakanishi, M. Matsumoto, D. Zaid, and T. Seya. 1995. Human glomerular epithelial cells synthesize and secrete the third component of complement. Nephron 70: 55-61.
  42. Seya, T., K. Nakamura, T. Masaki, C. Ichihara-Itoh, M. Matsumoto, and S. Nagasawa. 1995. Human factor H and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b. Molec. Immunol. 32: 355-360.
  43. Kitamura, M., M. Namiki, K. Matsumiya, K. Tanaka, M. Matsumoto, T. Hara, H. Kiyohara, M. Okabe, A. Okuyama, and T. Seya. 1995. Membrane cofactor protein (MCP, CD46) in seminal plasma is a prostasome-bound form with complement regulatory activity and measles virus neutralizing activity. Immunology 84: 626-632.
  44. Seya, T., M. Kurita, T. Hara, K. Iwata, M. Hatanaka, M. Matsumoto, Y. Yanagi, S. Ueda, and S. Nagasawa. 1995. Blocking measles virus infection by a recombinant soluble form of and monoclonal antibodies against membrane cofactor protein of complement (CD46). Immunology 84: 619-625.
  45. Seya, T., T. Hara, K. Iwata, S. Kuriyama, T. Hasegawa, Y. Nagase, S. Miyagawa, M. Matsumoto, M. Hatanaka, J. P. Atkinson, and S. Nagasawa. 1995. Purification and functional properties of soluble forms of membrane cofactor protein (MCP, CD46) of complement: Identification of forms increased in cancer patients' sera. Int. Immunol. 7: 727-736.
  46. Azuma, A., H. Yagita, T. Nishida, K. Yasukawa, T. Seya, K. Okumura, S. Kudoh, and H. Niitani. 1995. Differences of complement dependent cytotoxicities against human lung adenocarcinoma cell lines mediated by genetically rearranged anti-Lewis Y monoclonal antibody. Scand. J. Immunol. 42: 202-208.
  47. Kurita, M., Y. Yanagi, T. Hara, S. Nagasawa, M. Matsumoto, and T. Seya. 1995. Human lymphocytes are more susceptible to measles virus than granulocytes, which is attributable to the phenotypic differences of their membrane cofactor protein (CD46). Immunol. Lett. 48: 91-95.
  48. Hara, T., Y. Suzuki, M. Hatanaka, T. Semba, M. Matsumoto, and T. Seya. 1995. High expression level of CD46 (MCP) in human malignant cells: Implication of an alternatively spliced form containing the STA domain in CD46 up-regulation. Scand. J. Immunol. 42: 581-590.

    1994

  49. Iwata, K., T. Seya, H. Ariga, and S. Nagasawa. 1994. Expression of a hybrid complement regulatory protein, membrane cofactor protein (MCP)-decay-accelerating factor (DAF) on chinese hamster ovary cells; comparison of its regulatory effect with those of DAF and MCP. J. Immunol. 152: 3436-3444.
  50. Hazeki, K., T. Seya, O. Hazeki, and M. Ui. 1994. Involvement of islet-activating protein-sensitive GTP-binding protein in regulation of level and function of granulocyte complement receptor type 1 and type 3. Molec. Immunol. 31: 511-518.
  51. Nakanishi, I., A. Moutavarrik, T. Hara, M. Hatanaka, A. Hayashi, T. Syouji, N. Okada, E. Kitamura, Y. Tsubakihara, M. Matsumoto, and T. Seya. 1994. Identification and characterization of membrane cofactor protein (MCP, CD46) in human kidney. Eur. J. Immunol. 24: 1529-1535.
  52. Hara, T., H. Fukuda, T. Masaoka, M. Matsumoto, and T. Seya. 1994. Development of an ELISA assay for soluble CD35 (C3b/C4b receptor): high levels of soluble CD35 in LE-positive patients with hematological malignancies. Immunol. Lett. 41: 249-253.
  53. Ninomiya, N., K. Hazeki, Y. Fukui, T. Seya, Hazeki, O., and Ui, M. 1994. Involvement of phosphatidylinositol-3-kinase in Fcg receptor signaling. J. Biol. Chem. 269: 22732-22737.
  54. Iwata, K., T. Seya, H. Ariga, S. Ueda, and S. Nagasawa. 1994. Modulation of complement regulatory function and measles virus receptor function by the serine-threonine- rich domains of membrane cofactor protein (CD46). Biochem. J. 304: 169-175.
  55. Miyagawa, S., A. Terado, R. Shirakura, H. Matsuda, K. Iwata, S. Nagasawa, M. Matsumoto, and T. Seya. 1994. Effect of transfected DAF (CD55), MCP (CD46), and MCP/ DAF hybrid molecules on complement-mediated swine endothelial cell lysis. Transplantation 58: 834-840.
  56. Yanagi, Y., H-L. Hu, T. Seya, and H. Yoshikura. 1994. Measles virus infects mouse fibroblast cell lines, but its multiplication is severely restricted in the absence of CD46. Arch. Virol. 138: 39-53.
  57. Hatanaka, M., T. Seya, S. Inai, and A. Shimizu. 1994. The effects of mild reduction on the structure and function of the ninth component of complement (C9). Biochim. Biophys. Acta 1209: 117-122.
  58. Sakiyama, H., N. Inaba, T. Toyoguchi, Y. Okada, M. Matsumoto, H. Moriya, and H. Ohtsu. 1994. Immunolocalization of complement C1s and matrix metalloproteinase 9 (92kDa gelatinase/type IV collagenase) in the primary ossification center of the human femur. Cell Tissue Res. 277: 239-245.

    1993

  59. Miyagawa, S., R. Shirakura, G. Matsumiya, N. Fukushima, S. Nakata, H. Matsuda, M. Matsumoto, H. Kitamura, and T. Seya. 1993. Prolongation of discordant xenograft survival with anticomplement reagents, K76COOH and FUT175. Transplantation 55: 709-713.
  60. Matsumoto, M., and T. Seya. 1993. Homologous C3 deposition and homotypic cell adhesion in a human myeloid cell line, p39. Eur. J. Immunol. 23: 2270-2278
  61. Kojima, A., K. Iwata, T. Seya, M. Matsumoto, H. Ariga, J. P. Atkinson, and S. Nagasawa. 1993. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3 fragment deposition and cytolysis. J. Immunol. 151: 1519-1527.
  62. Okada, M., A. Kojima, C. Noda, M. Nonaka, M. Nonaka, K. Moriwaki, T. Kinoshita, T. Seya, and S. Natsuume-Sakai. 1993. Functional properties of allotypes of mouse complement regulatory protein, factor H: Difference of compatibility of each allotype with factor I of other species. Molec. Immunol. 30: 841-848.
  63. Sakuma, T., K. Kodama, T. Hara, H. Eshita, N. Shibata, M. Matsumoto, T. Seya, and Y. Mori. 1993. Levels of complement regulatory molecules in lung cancer: Disappearance of the D17 epitope of CD55 in small-cell carcinoma. Jap. J. Cancer Res. 84: 753-759.
  64. Seya, T., T. Hara, M. Matsumoto, H. Kiyohara, I. Nakanishi, T. Kinouchi, M. Okabe, A. Shimizu, and H. Akedo. 1993. Membrane cofactor protein (MCP, CD46) in seminal fluid and on spermatozoa in normal and sterile subjects. Eur. J. Immunol. 23: 1322-1327.
  65. Hatanaka, M., S. Inai, M. Matsumoto, S. Miyagawa, A. Kanamaru, M. Kawakita, Y. Yonemura, T. Masaoka, Y. Sugita, T. Seya, and A. Shimizu. 1993. Implication of membrane factors other than decay-accelerating factor (DAF, CD55) and CD59 in complement-mediated lysis of paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Clin. Immunol. Immunopathol. 69: 52-59.
  66. Miyagawa, S., R. Shirakura, G. Matsumiya, S. Nakata, H. Matsuda, M. Hatanaka, M. Matsumoto, H. Kitamura, and T. Seya. 1993. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate human complement-mediated damage of xeno-erythrocytes. Scand. J. Immunol. 38: 37-44.
  67. Moutabarrik, A., I. Nakanishi, M. Namiki, T. Hara, M. Matsumoto, M. Ishibashi, A. Okuyama, D. Zaid, and T. Seya. 1993. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46 (MCP), CD55 (DAF), and CD59 on human vascular endothelial cells. Cytokine Lymphokine Res. 12: 167-172.
  68. Hara, T., M. Matsumoto, T. Seya, Y. Fukumori, M. Hatanaka, S. Miyagawa, T. Kinoshita, and H. Akedo. 1993. Seminal plasma contains decay-accelerating factor (DAF, CD55) which lacks the reactivity with an anti-DAF monoclonal antibody, D17. Immunol. Lett. 37: 145-152.

    1992

  69. Matsumoto, M., T. Seya, and S. Nagasawa. 1992. Polymorphism and proteolytic fragments of granulocyte membrane cofactor protein (MCP, CD46) of complement. Biochem. J. 281: 493-499.
  70. Masaki, T., M. Matsumoto, R. Yasuda, I. Nakanishi, and T. Seya. 1992. Factor I-dependent regulation of human complement C4b of the classical pathway by C3b/C4b receptor (CR1, CD35) and membrane cofactor protein (MCP, CD46). J. Biochem. (Tokyo) 111: 573-578.
  71. Hatanaka, M., T. Seya, K. Fukumoto, T. Semba, and S. Inai. 1992. Probing C5b-8 binding sites in C9 with monoclonal antibodies: Participation of two separate epitopes of C9 in C5b-8 binding. Molec. Immunol. 29: 911-916.
  72. Hara, T., S. Kuriyama, H. Kiyohara, Y. Nagase, M. Matsumoto, and T. Seya. 1992. Soluble membrane cofactor protein (MCP, CD46): its presence in normal human plasma, tears, and seminal fluid. Clin. Exp. Immunol. 89: 490-494.
  73. Hara, T., A. Kojima, H. Fukuda, T. Masaoka, Y. Fukumori, M. Matsumoto, and T. Seya. 1992. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human hematological malignancies. Brit. J. Haematol. 82: 368-373.
  74. Seya, T., T. Hara, A. Kojima, M. Matsumoto, and H. Akedo. 1992. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59 and CR2 (CD21) and on cells lacking them. Int. Immunol. 4: 1361-1371.
  75. Hara, T., A. Kojima, M. Matsumoto, and T. Seya. 1992. Conditions for homologous complement C3 deposition induced on CD55-deficient human T cell lines. Life Sci. 11: 125-131.

    1991

  76. Seya, T., M. Okada, K. Hazeki, and S. Nagasawa. 1991. Regulatory system of guinea-pig complement C3b: tests for compatibility of guinea-pig factors H and I with human factors. Molec. Immunol. 28: 375-382.
  77. Seya, T., M. Okada, M. Matsumoto, K. Hong, T. Kinoshita, and J. P. Atkinson. 1991. Preferential inactivation of the C5 convertase of the alternative complement paghway by factor I and membrane cofactor protein (MCP). Molec. Immunol. 28: 1137-1148.
  78. Kojima, A., K. Hazeki, and T. Seya. 1991. Granulocyte-dependent extracellular cytotoxicity is enhanced by complement C3bi and independent of phagocytosis. Scand. J. Immunol. 33: 707-712.
  79. Matsumoto, M., Y. Sugita, and T. Seya. 1991. Alternative complement pathway-mediated myeloid cell cytotoxicity: Repertoire of membrane factors participating in regulation of C3-deposition and cytolysis. Eur. J. Immunol. 21: 1787-1792.
  80. Hong, K., T. Kinoshita, P. Pramoonjago, Y. U. Kim, J. Takeda, T. Seya, and K. Inoue. 1991. Reconstitution of C5 converatse of the alternative complement pathway with isolated C3b dimer and factors B and D. J. Immunol. 146: 1868-1873.
  81. Sayama, K., S. Shiraishi, Y. Shirakata, Y. Kobayashi, T. Seya, and Y. Miki. 1991. Expression and characterizaiton of membrane cofactor protein (MCP) in human skin. J. Invest. Dermatol. 97: 722-724.
  82. Fukuda, H., T. Seya, T. Hara, M. Matsumoto, T. Kinoshita, and T. Masaoka. 1991. Deficiency of decay-accelerating factor (DAF, CD55) in Non-Hodgkin's lymphoma. Immunol. Lett. 29: 205-210.
  83. Masaki, T., M. Matsumoto, R. Yasuda, R. P. Levine, H. Kitamura, and T. Seya. 1991. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives. J. Immunol. 147: 927-932.
  84. Seya, T., A. Kojima, T. Hara, K. Hazeki, Y. Sugita, and H. Akedo. 1991. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (MCP, CD46) and decay-accelerating factor (DAF, CD55). Immunobiol. 183: 115-124.
  85. Seya, T., M. Okada, T. Hara, M. Matsumoto, S. Miyagawa, and M. Oshimura. 1991. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1. Immunology 74: 719-724.
  86. Natsuume-Sakai, S., M. Okada, T. Seya, M. Nonaka, M. Nonaka, Y. Harada, and K. Moriwaki. 1991. The mouse factor H allotypes with multiple amino acid replacements H.1 and H.2 show indistinguishable cofactor activity for factor I. Eur. J. Immunogen. 18: 399-403.
  87. Sakiyama, H., K. Yamaguchi, K. Chiba, K. Nagata, C. Taniyama, M. Matsumoto, G. Suzuki, T. Tanaka, T. Tomoasawa, M. Yasukawa, K. Kuriiwa, S. Sakiyama, and H. Ohtsu. 1991. Biochmical characterization and tissue distribution of hamster complement C1s. J. Immunol. 146: 183-187.

    1990

  88. Seya, T., S. Nagasawa, and J. P. Atkinson. 1990. C4b-binding protein (C4bp) and a 60,000-dalton plasma protein share antigenic determinants with membrane cofactor protein (MCP) of complement. J. Immunol. 144: 2312-2320.
  89. Seya, T., H. Inoue, M. Okada, M. Matsumoto, H. Kitamura, T. Kinoshita, and H. Akedo. 1990. Proteolytic elimination of decay-accelerating factor (DAF) : Lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes. Molec. Immunol. 27: 69-78.
  90. Seya, T., M. Okada, H. Nishino, and J. P. Atkinson. 1990. Regualtion of proteolytic activity of complement factor I by pH: C3b/C4b receptor (CR1) and membrane cofactor protein (MCP) have different pH optima for factor I-mediated cleavage of C3b. J. Biochem. (Tokyo) 107: 310-315.
  91. Seya, T., T. Hara, M. Matsumoto, and H. Akedo. 1990. Quanatitative analysis of membrane cofactor protein (MCP) of complement: High expression of MCP on human leukemia cell lines, which is down-regulated during cell-differentiation. J. Immunol. 145: 238-245.
  92. Farries, T. C., T. Seya, R. A. Harrison, and J. P. Atkinson. 1990. Competition for binding sites on C3b by CR1, CR2, MCP, factor B and factor H. Complement Inflammation 7: 30-41.
  93. Seya, T., T. Hara, A. Uenaka, E. Nakayama, and H. Akedo. 1990. Application of protein A-rosette assay for screening monoclonal antibodies to complement regulatory proteins. Complement Inflammation 7: 78-89.
  94. Seya, T., M. Okada, K. Hazeki, and S. Nagasawa. 1990. Regulatory system of guinea-pig complement C3b: Two factor I-cofactor proteins on guinea-pig peritoneal granulocytes. Biochem. Biophys. Res. Commun. 170: 504-512.
  95. Seya, T., T. Hara, M. Matsumoto, Y. Sugita, and H. Akedo. 1990. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J. Exp. Med. 172: 1673-1680.
  96. Yamaguchi, K., H. Sakiyama, M. Matsumoto, H. Moriya and S. Sakiyama. 1990. Degradation of type I and II collagen by human C1s. FEBS Letters 268: 206-208.

    1989

  97. McNearney, T., L, Ballard, T. Seya, and J. P. Atkinson. 1989. Membrane cofactor protein of complement is present on human fibroblast, epitherial and endothelial cells. J. Clin. Invest. 84: 538-545.
  98. Seya, T., and J. P. Atkinson. 1989. Functional properties of membrane cofactor protein of complement. Biochem. J. 264: 581-588.
  99. Matsumoto, M., K. Nagaki, H. Kitamura, S. Kuramitsu, S. Nagasawa, and T. Seya. 1989. Probing the C4-binding site on C1s with monoclonal antibodies: evidence for a C4/C4b-binding site on the γ domain. J. Immunol. 142: 2743-2750.
  100. Matsumoto, M., K. Nagaki, T. Seya, and H. Kitamura. 1989. Acceleration of site to site transger of C1 by a monoclonal antibody to C1s. Molec. Immunol. 26: 697-703.
  101. Sasaki, T., K. Yonemasu, M. Matsumoto, and K. Nagaki. 1989. Characterization of C1q found in a patient with hypocomplementemic Vasculitis-urticaria syndrome. Microbiol. Immunol. 33: 413-422.

    1988年

  102. Seya, T., and S. Nagasawa. 1988. Heat-induced thiol-disulfide interchange reaction on the third component of human complement, C3. J. Biochem (Tokyo). 103: 792-796.
  103. Lublin, D. M., M. K. Linzesky, T. W. Post, M. A. Arce. M. M. Le Bearu, M. B. Rebentisch, R. S. Lemons, T. Seya, and J. P. Atkinson. 1988. Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP): evidence for inclusion in multi-gene family of complement-regulatory proteins. J. Exp. Med. 168: 181-194.
  104. Seya, T., L Ballard, N. Bora, V. Kumar, W. Cui, and J. P. Atkinson. 1988. Distribution of membrane cofactor protein (MCP) of complement in human peripheral blood cells. Eur. J. Immunol. 18: 1289-1294.
  105. Miyagawa, S., H. Hirose, R. Shirakura, Y. Naka, S. Nakata, Y. Kawashima, T. Seya, M. Matsumoto, A. Uenaka, and H. Kitamura. 1988. The mechanism of discordant xenograft rejection. Transplantation 46: 825-830.

    1987

  106. Ballard, L. B., T. Seya, J. F. Techman, D. M. Lublin, and J. P. Atkinson. 1987. A polymorphism of the complement regulatory protein MCP (membrane cofactor protein or gp 45-70). J. Immunol. 138: 3850-3855.
  107. Seya, T., M. W. Nickells, T. C. Farries, and J. P. Atkinson. 1987. Additional forms of human decay accelerating factor (DAF). J. Immunol. 139: 1260-1267.
  108. Kawasaki, A., H. Takada, S. Kotani, S. Inai, K. Nagaki, M. Matsumoto, K. Yokogawa, S. Kawata, S. Kusumoto, and T. Shiba. 1987. Activation of the human complement cascade by bacterial cell walls, peptidoglycans, water-solubole peptigoglycan components, and synthetic muramylpeptides: Studies on active components and structural requirements. Microbiol Immunol. 31: 551-569.

    1986

  109. Seya, T., S. Nagasawa, and J. P. Atkinson. 1986. Location of the interchain disulfide bonds of the fourth component of human complement (C4); Evidence based on the liberation of fragments secondary to thiol-disulfide interchange reactions. J. Immunol. 136: 4152-4156.
  110. Seya, T. J. R. Turner, and J. P. Atkinson. 1986. Purification and characterization of a membrane protein (gp 45-70) which is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163: 837-855.
  111. Holers, V. M., T. Seya, E. J. Brown, J. J. O'Shea, and J. P. Atkinson. 1986. Structural and functional analysis on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody. Complement 3: 63-78.
  112. Yu, G. H., V. M. Holers, T. Seya, L. B. Ballard, and J. P. Atkinson. 1986. Identification of a third component of complement-binding glycoprotein of human platelets. J. Clin. Invest. 78: 494-501.
  113. Nickells, M. W., T. Seya, V. M. Holers, and J. P. Atkinson. 1986. Analysis of C3b/C4b receptor (CR1) polymorphic variants by tryptic peptide mapping. Molec. Immunol. 23: 661-668.
  114. Nagaki, K., M. Tsuboi, M. Matsumoto, and H. Kitamura. 1986. A simple one-step hemolytic assay of the first component of human complement (C1) with polyethylene glycol-treated human serum: details of the assay procedures and its application to the C1 activation study. J. Clin. Lab. Immunol. 21: 141-146.
  115. Matsumoto, M., and K. Nagaki. 1986. Functional analysis of activated C1s, a subcomponent of the first component of human complement, by monoclonal antibodies. J. Immunol. 137: 2907-2912.

    1985

  116. Seya, T., and S. Nagasawa. 1985. Limited proteolysis of complement protein C3b by regualtory enzyme C3b inactivator; Isolation and characterization of a biologically active fragment, C3d, g. J. Biochem (Tokyo). 97: 373-382.
  117. Matsuda, T., T. Seya, and S. Nagasawa. 1985. Location of the interchain disulfide bonds of the third component of human complment. Biochem. Biophys. Res. Commun. 127: 264-269.
  118. Seya, T., V. M. Holers, and J. P. Atkinson. 1985. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1), and comparison to H, C4b-binding protein (C4bp), and decay-accelerating factor (DAF). J. Immunol. 135: 2661-2667.
  119. Seya, T., S. Nagasawa, and J. P. Atkinson. 1985. Generation of bioactive kallikrein-derived fragment, C3d-K, by HANE plasma. Clin. Exp. Immunol. 62: 208-216.
  120. Seya, T., S. Nagasawa, M. Matsukura, H. Hasegawa, and J. P. Atkinson. 1985. Generation of C3d,g and C3d by urokinase-treated plasma in association with fibrinolysis. Complement 2: 165-174.

    1984

  121. Kitamura, H., M. Matsumoto, and K. Nagaki. 1984. C3-independent immune haemolysis: haemolysis of EAC14oxy2 cells by C5-C9 without participation of C3. Immunology 53; 575-582.

    1983

  122. Hasegawa, H., H. Nagata, T. Murakoshi, M. Yamauchi, Y. Oguma, H. Takei, T. Seya, and M. Murao. 1983. Coagulation-fibrinolytic analysis in patients with lung cancer. Acta Hematol. Jap. 46: 197-203.
  123. Seya, T., and S. Nagasawa. 1983. Isolation of an iC3b forming enzyme from peritoneal polymorphonuclear leukocytes of guinea-pigs. Biochem. Biophys. Res. Commun. 117: 413-419.

    1982

  124. Hasegawa, H., H. Nagata, M. Yamauchi, T. Murakoshi, Y. Oguma, H. Takei, T. Seya, and M. Murao. 1982. Role of dextran sulfate in urokinase therapy and evaluation of the effects by estimation of plasmin inhibitor, fibrinogenolytic degradation products and fibrinolytic degradation products. Jap. Heart J. 23: 339-347.
  125. Seya, T., and S. Nagasawa. 1982. A fluorescent method for determination of C3b inactivator. Clin. Chim. Acta. 119: 189-196.

    1981

  126. Seya, T., and S. Nagasawa. 1981. Limited proteolysis of the third component of human complement, C3, by heat treatment. J. Biochem (Tokyo). 89: 659-664.

    1980

  127. Hasegawa, H., Y. Oguma, H. Takei, T. Seya, M. Yamauchi, T. Murakaoshi, H. Nagata, and M. Murao. 1980. Assay of heaprin in plasma using a chromogenic substrate and its clinical applications. Jap. Heart J. 21: 367-380.
  128. Nagaki, K., M. Matsumoto, and H. Kitamura. 1980. A low molecular weight inhibitor of the alternative complement pathway: I. Its isolation from human urine and the reaction mechanism. Immunology 41: 789-798.

    1973-1979

  129. Hiramatsu, M., N. Okabe, and K. Tomita. 1973. Preparation and properties of lysozyme modified by Fluorescein-isothiocyanate. J. Biochem. 73: 971-978.
  130. Kitamura, H., M. Matsumoto, and S. Inai. 1976. Necessity of the divalent cation in the reaction between EAC1-8hu and C9gp. Int. Archs. Allergy appl. Immunol. 51: 265-271.
  131. Fujita, T., M. Takiuchi, M. Matsumoto, K. Nagaki, and S. Inal. 1977. C3- and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes. Int. Archs. Allergy appl. Immunol. 53: 303-309.